Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach
The most commonly used oral drug in treating type 2 diabetes (T2DM) after metformin are sufonylureas (SUs) based on the confidence gained over the several decades and because of its cheaper cost. Unfortunately, SUs are associated with secondary failure and sometimes associated with therapy related s...
Main Author: | Awadhesh Kumar Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=617;epage=623;aulast=Singh |
Similar Items
-
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
by: Young-Hwan Park, et al.
Published: (2024-03-01) -
Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
by: E V Oskola, et al.
Published: (2013-09-01) -
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
by: Soo Lim, et al.
Published: (2023-01-01) -
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
by: Byung Wan Lee, et al.
Published: (2023-06-01) -
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)